An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
מצבים רפואיים
Metastatic Hormone-sensitive Prostate Cancer
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
University of California San Diego - Moores Cancer Center, La Jolla, California, United States
Contact: Principal Investigator (Rana McKay)Saint Johns Cancer Institute, Santa Monica, California, United States
Contact: Principal Investigator (Przemyslaw Twardowski)Rocky Mountain Cancer Centers, Denver, Colorado, United States
Contact: Principal Investigator (Manojkumar Bupathi)Yale Cancer Center, New Haven, Connecticut, United States
Contact: Principal Investigator (Daniel P Petrylak)Advanced Urology Ins Daytona Beach, Daytona Beach, Florida, United States
Contact: Principal Investigator (Samuel Lawindy)Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
Contact: Principal Investigator (Shahid Sattar Ahmed)Associated Urological Specialists, Chicago Ridge, Illinois, United States
Contact: Principal Investigator (Aaron Berger)American Oncology Partners PA Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Contact: Principal Investigator (Garrett Diltz)Mass General Hospital, Boston, Massachusetts, United States
Contact: Principal Investigator (Xin Gao)Michigan Institute of Urology, West Bloomfield, Michigan, United States
Contact: Principal Investigator (Jason Hafron)XCancer Omaha LLC, Omaha, Nebraska, United States
Contact: Principal Investigator (Luke Nordquist)Perlmutter Cancer Centre, New York, New York, United States
Contact: Principal Investigator (Andrew Laccetti)Associated Med Professionals of NY, Syracuse, New York, United States
Contact: Principal Investigator (Christopher Pieczonka)Montefiore Medical Center, The Bronx, New York, United States
Contact: Principal Investigator (Benjamin A Gartrell)MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States
Contact: Principal Investigator (Laurence Belkoff)Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Daniel Geynisman)Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Contact: Principal Investigator (Neal D Shore)Tennessee Oncology, Nashville, Tennessee, United States
Contact: Principal Investigator (Benjamin Garmezy)Urology San Antonio, San Antonio, Texas, United States
Contact: Principal Investigator (Jose De La Cerda)Virginia Oncology Associates, Norfolk, Virginia, United States
Contact: Principal Investigator (Mark Fleming)Fred Hutch Cancer Research, Seattle, Washington, United States
Contact: Principal Investigator (Michael Schweizer)Novartis Investigative Site, Adelaide, South Australia, Australia
Novartis Investigative Site, Clayton, Victoria, Australia
Novartis Investigative Site, Fortaleza, Ceará, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, Vancouver, British Columbia, Canada
Novartis Investigative Site, Halifax, Nova Scotia, Canada
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Beijing, Chaoyang, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Brno, Czechia
Novartis Investigative Site, Olomouc, Czechia
Novartis Investigative Site, Prague, Czechia
Novartis Investigative Site, Nice, Alpes Maritimes, France
Novartis Investigative Site, Marseille, France
Novartis Investigative Site, Quint-Fonsegrives, France
Novartis Investigative Site, Suresnes, France
Novartis Investigative Site, Düsseldorf, North Rhine-Westphalia, Germany
Novartis Investigative Site, Hamburg, Germany
Novartis Investigative Site, Lübeck, Germany
Novartis Investigative Site, Nürtingen, Germany
Novartis Investigative Site, Asti, AT, Italy
Novartis Investigative Site, Padova, PD, Italy
Novartis Investigative Site, Trento, TN, Italy
Novartis Investigative Site, Orbassano, TO, Italy
Novartis Investigative Site, Verona, VR, Italy
Novartis Investigative Site, Zwolle, Overijssel, Netherlands
Novartis Investigative Site, Dordrecht, South Holland, Netherlands
Novartis Investigative Site, Hoofddorp, Netherlands
Novartis Investigative Site, Schiedam, Netherlands
Novartis Investigative Site, Kielce, Poland
Novartis Investigative Site, Olsztyn, Poland
Novartis Investigative Site, Oświęcim, Poland
Novartis Investigative Site, Skorzewo, Poland
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Santander, Cantabria, Spain
Novartis Investigative Site, Badajoz, Extremadura, Spain
Novartis Investigative Site, Lugo, Galicia, Spain
Novartis Investigative Site, Pamplona, Navarre, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Córdoba, Spain
Novartis Investigative Site, Kaohsiung City, Taiwan
Novartis Investigative Site, Tainan, Taiwan
מובילי המחקר
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals